This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent issue of the ARCHIVES, Charrow et al,¹ as US regional coordinators for the International Collaborative Gaucher Group (ICGG) registry, present their recommendations for diagnosis, evaluation, and monitoring of patients with Gaucher disease. As the largest referral clinic for Gaucher disease outside the United States, our recommendations regarding monitoring differ to some extent from those enumerated in the above-mentioned article. We feel that the recommendation to use magnetic resonance imaging (MRI) or computed tomography (CT) for repeated evaluation of visceral involvement is probably unnecessary outside the constraints of a clinical trial. Ultrasound is highly accurate, universally available, inexpensive, involves no exposure to radiation, and the measurements can be easily converted for comparison to MRI² and CT.³ Similarly, the recommendations for technetium Tc 99m sulfur colloid nuclear scanning and quantitative chemical shift MRI for routine bone assessment are problematic, not being universally available, and not clearly adding to the . . . [Full Text of this Article]